Good-Bye Reading Glasses! FDA Approves Vizz Eye Drops

Report Issue

Please complete the required fields.

Your Name

Email

Reason (required)
This post contains broken linksPost has incorrect informationPost has spamCopyright IssueOther

Description

Submit

Lenz Therapeutics’ Vizz eye drops improve near vision for up to 10 hours, offering millions a new alternative to reading glasses and bifocals.

The U.S. Food and Drug Administration (FDA) has approved the use of “Vizz” eye drops, developed by Lenz Therapeutics, for the treatment of presbyopia, also known as tired vision, in adults. The medication is expected to reach pharmacies starting in October 2025.

The pharmaceutical company highlighted that these eye drops, based on the compound aceclidine, improve near vision in people with presbyopia for up to 10 hours with just one daily application—a potential “game changer” for millions who struggle with age-related vision loss.

Aceclidine works by contracting the pupil with minimal stimulation of the ciliary muscle. Vizz specifically contracts the iris sphincter muscle, creating a pinhole effect that reduces the pupil to less than 2 mm. This increases the depth of focus, allowing significant improvement in near vision without causing a myopic shift, according to the company’s statement.

“I believe this will be a very useful solution for both optometrists and ophthalmologists, who can now offer patients a highly effective and much-needed treatment for presbyopia—one that could immediately become the standard of care,” said clinical investigator Marc Bloomenstein of Schwartz Laser Eye Care Center in Arizona.

The FDA’s approval of Vizz was based on results from three Phase 3 clinical trials:

• Clarity 1 and Clarity 2, which evaluated safety and effectiveness in 466 participants who used one daily dose for 42 days.
• Clarity 3, which studied long-term safety in 217 participants treated once daily for six months.

In the first two studies, Vizz met all proposed goals, showing it could improve near vision within 30 minutes of application and maintain the effect for up to 10 hours. The improvement was reproducible and consistent across both trials.

The drops also demonstrated good tolerance. Across more than 30,000 treatment days in the three trials, no serious adverse effects related to treatment were reported. The most common side effects were application-site irritation, blurred vision, and headaches—all generally mild, temporary, and self-resolving.

What is “Tired Vision” (Presbyopia)?

Tired vision, or presbyopia, is a natural, age-related condition in which the eye gradually loses its ability to focus on close objects. It typically begins around age 40–45 and progresses slowly.

This happens because the lens of the eye becomes less flexible over time, making it harder to adjust focus for near tasks such as reading, using a smartphone, or sewing. Common symptoms include:

• Needing to hold reading material farther away
• Eye strain or headaches during near work
• Blurry vision at close distances

Presbyopia is not an eye disease but a universal part of aging. Until now, it has been managed with reading glasses, bifocals, multifocal contact lenses, or surgery. Treatments like Vizz represent a new non-invasive option for patients who prefer to avoid glasses.